Site-specific drug delivery company Talima Therapeutics, Inc. announced today that they have raised $19 million in an oversubscribed second funding round. The funding will allow the company to proceed through Phase II clinical trials.
From: www.redorbit.com
Talima Therapeutics Secures $19 Million Series B
Posted by Ruslan Abuzant at 10:19 AM
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment